EGRX Company Profile and Key Details
NASDAQ : EGRX
Eagle Pharmaceuticals
$0.37
-0.0102-2.72%
At Close 4:00 PM69.01
BESG ScoreESG Rating
Price Chart
Stock Price Today
Eagle Pharmaceuticals, Inc. (EGRX) stock declined over -2.72%, trading at $0.37 on OTC, down from the previous close of $0.38. The stock opened at $0.00, fluctuating between $0.00 and $0.37 in the recent session.
Stock Snapshot
0.3752
Prev. Close
4.8M
Market Cap
0.0024
Day Low
5.21
P/E Ratio
0.07
EPS (TTM)
0.29
Cash Flow per Share
0
Open
12.99M
Number of Shares
0.37
Day High
88.42%
Free Float in %
19.25
Book Value
1.53K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 19, 2026 | 0.00 | 0.37 | 0.00 | 0.37 | 1.53K |
| May 18, 2026 | 0.38 | 0.38 | 0.38 | 0.38 | 100 |
| May 11, 2026 | 0.09 | 0.38 | 0.09 | 0.38 | 2.19K |
| May 06, 2026 | 0.09 | 0.38 | 0.09 | 0.38 | 1.53K |
| Apr 23, 2026 | 0.39 | 0.39 | 0.06 | 0.38 | 578 |
| Apr 16, 2026 | 0.35 | 0.35 | 0.35 | 0.35 | 102 |
| Apr 07, 2026 | 0.23 | 0.34 | 0.23 | 0.34 | 1.32K |
| Apr 02, 2026 | 0.25 | 0.25 | 0.25 | 0.25 | 1.03K |
| Apr 01, 2026 | 0.37 | 0.37 | 0.09 | 0.09 | 665 |
| Mar 24, 2026 | 0.09 | 0.15 | 0.09 | 0.15 | 3.06K |
| Mar 19, 2026 | 0.09 | 0.09 | 0.09 | 0.09 | 214 |
| Mar 09, 2026 | 0.25 | 0.34 | 0.25 | 0.34 | 469 |
| Feb 26, 2026 | 0.00 | 0.55 | 0.00 | 0.20 | 401 |
| Feb 19, 2026 | 0.20 | 0.20 | 0.20 | 0.20 | 474 |
| Feb 12, 2026 | 0.25 | 0.25 | 0.25 | 0.25 | 2.2K |
| Feb 05, 2026 | 0.25 | 0.25 | 0.25 | 0.25 | 155 |
| Feb 03, 2026 | 0.10 | 0.25 | 0.10 | 0.25 | 2.75K |
| Jan 30, 2026 | 0.33 | 0.33 | 0.25 | 0.25 | 5.11K |
| Jan 21, 2026 | 0.10 | 0.70 | 0.10 | 0.70 | 1.35K |
| Jan 14, 2026 | 0.22 | 0.85 | 0.22 | 0.85 | 483 |
Contact Details
About Company
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Company Information
| Employees | 134 |
| Beta | 0.31 |
| Sales or Revenue | $316.61M |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Stock Peers
MKGAF
-6.5-3.38%
MERCK Kommanditgesellschaft auf Aktien$186.00HKMPY-0.87-1.69%
Hikma Pharmaceuticals PLC$50.66SGIOF00
Shionogi & Co., Ltd.$43.89ESALF00
Eisai Co., Ltd.$43.00MKKGY-0.85-2.24%
MERCK Kommanditgesellschaft auf Aktien$37.11IPSEY00
Ipsen S.A.$33.00TKPHF00
Takeda Pharmaceutical Company Limited$26.83TEVJF5.26+43.91%
Teva Pharmaceutical Industries Limited$17.24APNHY00
Aspen Pharmacare Holdings Limited$12.52TAIPY00
Taisho Pharmaceutical Holdings Co., Ltd.$12.00Company Overview
Eagle Pharmaceuticals, Inc. (OTC:EGRX) closed at $0.36 USD, losing -$0.01 (-2.72%) from the previous close of $0.38. The stock is currently mid-range between its 52-week high and low $0.09 and $3.87. With a market capitalization of about $4.80 million, Eagle Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.60). Key stats such as the average daily volume over the past year has been around 3.79 thousand shares, volume is running light vs its 52-week average. Headquartered in Woodcliff Lake, NJ, Eagle Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Michael Graves, the company employs approximately 134 people and listed since February 12, 2014. Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.
Technical Performance
EGRX has shown weak momentum, losing -2.77% over the past week and -85.34% over the past quarter, though year-to-date performance is down -83.27%. Short-term trend indicators are bullishly aligned (SMA20 -45.49%, SMA50 -50.91%, SMA200 -55.9%). The stock’s 14-day RSI is 20.52 (weak momentum), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -85.91% below its high and over 18.89% above its low. Average 10-day trading volume of 1.27 thousand shares is slightly above the 3-month average of 1.01 thousand, indicating heightened recent market interest.
Valuation Metrics
Eagle Pharmaceuticals, Inc. trades at a P/E ratio of 0.13, slightly below the S&P 500 average, with a price-to-sales ratio of 0.02 and a price-to-book ratio of 0.02 suggesting the stock is closer to book value. The P/FCF stands at 0.16, also above market averages.
Dividend & Fair Value
Eagle Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $43.85. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Eagle Pharmaceuticals, Inc. generated EPS of $0.85 over the past year. Five-year average earnings growth is 11.34%. Wall Street analysts project EPS growth of 2.7% annually over the next five years. Eagle Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 09, 2023, missed forecasts by -124.77%. The prior quarter beat by 12.38%. Over the last six quarters, Apple has recorded several small beats. These include -50.16% in August 09, 2022.
Shareholding & Insider Activity
Eagle Pharmaceuticals, Inc. has 12.96 million shares outstanding. The public float is 4.52 million shares, elevated short interest at 4.19% of float. This equals 350.53 thousand shares. The short ratio is 3.91 days. Institutional investors hold 62.47% of the float. Insiders own 11.64%. Braunstein Douglas L holds 811.78 thousand shares, Hudson Executive Capital LP has 732.78 thousand shares and Tarriff Scott has 545.45 thousand shares.
Price Forecast & Outlook
Our AI price prediction model suggests that Eagle Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.11%, with price expected at $0.35 by June 02, 2026, within a range of $0.18 to $0.52 3-Month Outlook: Projected rise of 9.59%, reaching $0.40 by August 14, 2026, with a range of $0.25 to $0.52. 1-Year Outlook: Projected gain of 100.0%, with price at $0.73 by May 19, 2027, within a range of $0.00 to $0.67.
Key Takeaways
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shares are down -83.27% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Eagle Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 0.13. Analyst sentiment is cautious, with the majority of ratings in Underweight territory and a mean price target of $62.39, suggesting 16993.15% upside. Our AI forecast model points to short-term weakness (-4.11% over two weeks), a medium-term rise (9.59% over three months), and a longer-term gain (100.0% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Eagle Pharmaceuticals, Inc. (EGRX) stock price?
Eagle Pharmaceuticals, Inc. (OTC: EGRX) stock price is $0.37 in the last trading session. During the trading session, EGRX stock reached the peak price of $0.37 while $0.00 was the lowest point it dropped to. The percentage change in EGRX stock occurred in the recent session was -2.72% while the dollar amount for the price change in EGRX stock was - $0.01.
EGRX's industry and sector of operation?
The OTC listed EGRX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Eagle Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of EGRX?
Mr. Brian Joseph Cahill
Chief Financial Officer
Mr. John Kimmet
Executive Vice President of Marketing Oncology & Acute Care
Mr. Reiner Nowak
Executive
Dr. Gaozhong Zhu Ph.D.
Senior Vice President of Pharmaceutical Devel.
Ms. Debra M. Hussain
Senior Vice President & Head of Commercial
Mr. Scott L. Tarriff
Founder, Pres, Chief Executive Officer & Director
Mr. Ryan Debski
Executive Vice President, Gen. Counsel & Chief Compliance Officer
Mr. Reed McClung
Executive Vice President of Oncology Bus. Devel.
Mr. Daniel O'Connor
Executive Vice President, Chief Strategy Officer & Head of Corporation Devel.
Dr. Valentin R. Curt M.D.
Senior Vice President of Clinical Drug Devel.
Chief Financial Officer
Mr. John Kimmet
Executive Vice President of Marketing Oncology & Acute Care
Mr. Reiner Nowak
Executive
Dr. Gaozhong Zhu Ph.D.
Senior Vice President of Pharmaceutical Devel.
Ms. Debra M. Hussain
Senior Vice President & Head of Commercial
Mr. Scott L. Tarriff
Founder, Pres, Chief Executive Officer & Director
Mr. Ryan Debski
Executive Vice President, Gen. Counsel & Chief Compliance Officer
Mr. Reed McClung
Executive Vice President of Oncology Bus. Devel.
Mr. Daniel O'Connor
Executive Vice President, Chief Strategy Officer & Head of Corporation Devel.
Dr. Valentin R. Curt M.D.
Senior Vice President of Clinical Drug Devel.
How EGRX did perform over past 52-week?
EGRX's closing price is 329.41% higher than its 52-week low of $0.09 where as its distance from 52-week high of $3.87 is -90.57%.
How many employees does EGRX have?
Number of EGRX employees currently stands at 134.
Link for EGRX official website?
Official Website of EGRX is: https://www.eagleus.com
How do I contact EGRX?
EGRX could be contacted at phone 201 326 5300 and can also be accessed through its website. EGRX operates from 50 Tice Boulevard, Woodcliff Lake, NJ 07677, United States.
How many shares of EGRX are traded daily?
EGRX stock volume for the day was 1.53K shares. The average number of EGRX shares traded daily for last 3 months was 3.79K.
What is the market cap of EGRX currently?
The market value of EGRX currently stands at $4.80M with its latest stock price at $0.37 and 12.99M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep